A multicentre observational study of the efficacy and safety of Sodium Oligomannate Capsules in the treatment of Alzheimer's disease

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000039219

Enrollment

Unknown

Registered

2020-10-22

Start date

2020-11-01

Completion date

Unknown

Last updated

2021-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer disease

Interventions

Take Sodium Oligomannate capsules group:No intervention

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who voluntarily purchase and take Sodium Oligomannate capsules.

Exclusion criteria

Exclusion criteria: Nil.

Design outcomes

Primary

Measure	Time frame
Adverse Reaction;Therapeutic Effect;	—

Countries

China

Contacts

Public ContactYang Lü

The First Affiliated Hospital of Chongqing Medical University

lyu_yang@126.com+86 13618236535

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026